{"id":"non-pegylated-liposomal-doxorubicin","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"20-50%","effect":"Mucositis"},{"rate":"2-5%","effect":"Cardiotoxicity"}]},"_chembl":{"chemblId":"CHEMBL53463","moleculeType":"Small molecule","molecularWeight":"543.53"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This process ultimately leads to cell death, making it an effective treatment for various types of cancer. The liposomal formulation helps to reduce the side effects associated with traditional doxorubicin by targeting the drug directly to the tumor site, minimizing exposure to healthy tissues.","oneSentence":"Non-pegylated liposomal doxorubicin is a chemotherapy medication that works by intercalating DNA strands, thereby inhibiting the progression of the enzyme topoisomerase II and inducing apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:14.321Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Ovarian cancer"},{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT05467670","phase":"PHASE2","title":"Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexander B Olawaiye, MD","startDate":"2023-03-30","conditions":"Ovarian Cancer","enrollment":16},{"nctId":"NCT05411237","phase":"PHASE3","title":"Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2026-09","conditions":"Kaposi Sarcoma, HIV-1-infection, AIDS-related Kaposi Sarcoma","enrollment":130},{"nctId":"NCT06981637","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)","status":"RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2025-12-31","conditions":"Advanced Soft Tissue Sarcoma","enrollment":81},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT02916316","phase":"","title":"Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-02-12","conditions":"Lymphoma, Large B-Cell, Diffuse Large B-Cell","enrollment":127},{"nctId":"NCT01564056","phase":"PHASE3","title":"Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-04-12","conditions":"Breast Cancer","enrollment":1989},{"nctId":"NCT02891824","phase":"PHASE3","title":"ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2016-09-22","conditions":"Ovarian Cancer","enrollment":614},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT03598270","phase":"PHASE3","title":"Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2018-11-21","conditions":"Recurrent Ovarian Carcinoma","enrollment":417},{"nctId":"NCT01619111","phase":"PHASE3","title":"DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs","status":"COMPLETED","sponsor":"Prof. Wolfgang Janni","startDate":"2012-02","conditions":"HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells","enrollment":105},{"nctId":"NCT01783535","phase":"PHASE2","title":"Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-19","conditions":"Retinoblastoma","enrollment":174},{"nctId":"NCT02456857","phase":"PHASE2","title":"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-12","conditions":"Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma","enrollment":17},{"nctId":"NCT00574730","phase":"NA","title":"CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-05-23","conditions":"Non-Hodgkins Lymphoma","enrollment":27},{"nctId":"NCT01802749","phase":"PHASE3","title":"Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2013-11","conditions":"Recurrent Ovarian Cancer","enrollment":406},{"nctId":"NCT02562378","phase":"PHASE1","title":"T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"MedSIR","startDate":"2015-10","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT05181202","phase":"","title":"Biomarkers of Liposomal Doxorubicin Induced Hypersensitivity Reaction in Breast Cancer Patients","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-02-07","conditions":"Liposomal Doxorubicin Induced Hypersensitivity Reaction in Breast Cancer Patients","enrollment":20},{"nctId":"NCT04679064","phase":"PHASE3","title":"Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-12-01","conditions":"Ovarian Cancer","enrollment":427},{"nctId":"NCT04887961","phase":"PHASE2","title":"Reprab Study: PLD + Trabectedin Rechallenge","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-10-01","conditions":"Relapsed Ovarian Cancer","enrollment":64},{"nctId":"NCT03699449","phase":"PHASE2","title":"An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2018-11-26","conditions":"Platinum-resistant Recurrent Ovarian Cancer","enrollment":104},{"nctId":"NCT00296010","phase":"PHASE3","title":"Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2005-08","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT00101010","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-09","conditions":"Lymphoma","enrollment":80},{"nctId":"NCT02163720","phase":"","title":"Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2014-07-10","conditions":"Ovarian Cancer","enrollment":101},{"nctId":"NCT01935492","phase":"PHASE3","title":"8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Borstkanker Onderzoek Groep","startDate":"2010-11","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer","enrollment":420},{"nctId":"NCT04101812","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Second Hospital","startDate":"2019-09-17","conditions":"Muscle Invasive Bladder Cancer","enrollment":60},{"nctId":"NCT03952572","phase":"PHASE3","title":"Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma","status":"UNKNOWN","sponsor":"Peking University","startDate":"2019-05-10","conditions":"Peripheral T-cell Lymphoma","enrollment":244},{"nctId":"NCT03123770","phase":"PHASE4","title":"Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2016-12","conditions":"Breast Cancer","enrollment":384},{"nctId":"NCT00255801","phase":"PHASE2","title":"Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2005-11","conditions":"Lymphoma","enrollment":37},{"nctId":"NCT00074087","phase":"PHASE2","title":"Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2003-10","conditions":"Lymphoma","enrollment":49},{"nctId":"NCT00389818","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-01","conditions":"Lymphoma","enrollment":43},{"nctId":"NCT03446495","phase":"","title":"An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer","status":"UNKNOWN","sponsor":"Suriya Yessentayeva","startDate":"2017-03-28","conditions":"Ovarian Cancer","enrollment":60},{"nctId":"NCT00744354","phase":"PHASE1","title":"Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2008-10","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":32},{"nctId":"NCT02953184","phase":"PHASE2","title":"Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Jilin University","startDate":"2016-11","conditions":"Antineoplastic Combined Chemotherapy Protocols","enrollment":160},{"nctId":"NCT03359694","phase":"PHASE3","title":"Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2017-12","conditions":"Susceptibility, Genetic, Chemotherapy Effect","enrollment":300},{"nctId":"NCT00244985","phase":"PHASE1, PHASE2","title":"Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2005-09","conditions":"Lymphoma","enrollment":42},{"nctId":"NCT00184002","phase":"PHASE2","title":"Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2003-01-10","conditions":"Non-Hodgkin's Lymphoma","enrollment":68},{"nctId":"NCT02125344","phase":"PHASE3","title":"A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2014-12","conditions":"Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II","enrollment":961},{"nctId":"NCT00727961","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-11-09","conditions":"Ovarian Neoplasms","enrollment":58},{"nctId":"NCT00209209","phase":"PHASE3","title":"Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL","status":"UNKNOWN","sponsor":"European Mantle Cell Lymphoma Network","startDate":"2004-01-14","conditions":"Lymphoma, Mantle-Cell","enrollment":570},{"nctId":"NCT02996617","phase":"PHASE4","title":"PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2016-11","conditions":"Lymphoma,Non-Hodgkin","enrollment":240},{"nctId":"NCT01172223","phase":"PHASE1, PHASE2","title":"Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer","status":"COMPLETED","sponsor":"Prof Dirk Elling","startDate":"2007-09","conditions":"Breast Cancer","enrollment":81},{"nctId":"NCT00006029","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2000-07","conditions":"Lymphoma","enrollment":91},{"nctId":"NCT02428751","phase":"PHASE3","title":"R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma","status":"UNKNOWN","sponsor":"Wenqi Jiang","startDate":"2015-09","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":216},{"nctId":"NCT01495884","phase":"PHASE1, PHASE2","title":"The Myocet/Lapatinib Study. ICORG 10-03, V5","status":"TERMINATED","sponsor":"Cancer Trials Ireland","startDate":"2011-03","conditions":"Her2 Positive Metastatic Breast Cancer","enrollment":11},{"nctId":"NCT00377559","phase":"PHASE2","title":"Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Catharina Ziekenhuis Eindhoven","startDate":"2006-05","conditions":"Breast Cancer, Neoplasm Metastasis","enrollment":70},{"nctId":"NCT00377780","phase":"PHASE2","title":"Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Laurence J.C. van Warmerdam","startDate":"2006-08","conditions":"Breast Cancer, Neoplasm Metastasis","enrollment":60},{"nctId":"NCT00851552","phase":"PHASE2","title":"Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2009-01","conditions":"Lymphoma","enrollment":9},{"nctId":"NCT00183976","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2005-04","conditions":"Non-Hodgkin's Lymphoma, Burkitt Lymphoma, Primary Effusion Lymphomas","enrollment":15},{"nctId":"NCT01367028","phase":"PHASE2","title":"A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"2011-06","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT00016172","phase":"PHASE1","title":"ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-11","conditions":"Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00004162","phase":"PHASE1","title":"Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"1997-06","conditions":"Lymphoma","enrollment":48},{"nctId":"NCT00237627","phase":"PHASE1, PHASE2","title":"Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2001-05","conditions":"Breast Cancer, Leukemia, Lymphoma","enrollment":107},{"nctId":"NCT01051362","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2006-02","conditions":"Non-small Cell Lung Cancer","enrollment":48},{"nctId":"NCT00600977","phase":"PHASE2","title":"Liposomal Anthracyclin in the Treatment of Elderly ALL","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2002-03","conditions":"Acute Lymphoblastic Leukemia","enrollment":60},{"nctId":"NCT00120198","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients","status":"TERMINATED","sponsor":"Geriatric Oncology Consortium","startDate":"2005-03","conditions":"Non-Hodgkin's Lymphoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"ANAEMIA"},{"count":3,"reaction":"BONE LESION"},{"count":3,"reaction":"CYTOPENIA"},{"count":3,"reaction":"DISEASE PROGRESSION"},{"count":3,"reaction":"ELECTROCARDIOGRAM REPOLARISATION ABNORMALITY"},{"count":3,"reaction":"FEBRILE NEUTROPENIA"},{"count":2,"reaction":"EJECTION FRACTION ABNORMAL"},{"count":2,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":2,"reaction":"OFF LABEL USE"},{"count":2,"reaction":"PANCYTOPENIA"}],"_approvalHistory":[],"publicationCount":65,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Myocet"],"phase":"phase_3","status":"active","brandName":"non-pegylated liposomal doxorubicin","genericName":"non-pegylated liposomal doxorubicin","companyName":"GBG Forschungs GmbH","companyId":"gbg-forschungs-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Non-pegylated liposomal doxorubicin is a chemotherapy medication that works by intercalating DNA strands, thereby inhibiting the progression of the enzyme topoisomerase II and inducing apoptosis in cancer cells. Used for Metastatic breast cancer, Ovarian cancer, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}